**Trader consensus heavily favors no hantavirus vaccine approval in 2026, reflecting the early-stage status of all candidates.** Authoritative sources including the WHO and CDC confirm no licensed vaccine exists for New World hantaviruses such as Andes virus, with only limited inactivated products used regionally in Asia for other strains. Promising mRNA and DNA candidates from groups like UTMB, USAMRIID, and Moderna-Korea University collaborations remain in preclinical or Phase 1 testing, with no Phase 3 efficacy trials underway. The rarity of cases complicates large-scale human studies, and standard regulatory timelines—absent emergency funding or accelerated pathways—make licensure this year improbable despite heightened attention from the 2026 MV Hondius outbreak. New data releases or trial initiations could shift sentiment, but current evidence supports the market-implied odds.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Hantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
4% 概率
$136,356 交易量
$136,356 交易量
2026-12-31
4% 概率
$136,356 交易量
$136,356 交易量
2026-12-31
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus heavily favors no hantavirus vaccine approval in 2026, reflecting the early-stage status of all candidates.** Authoritative sources including the WHO and CDC confirm no licensed vaccine exists for New World hantaviruses such as Andes virus, with only limited inactivated products used regionally in Asia for other strains. Promising mRNA and DNA candidates from groups like UTMB, USAMRIID, and Moderna-Korea University collaborations remain in preclinical or Phase 1 testing, with no Phase 3 efficacy trials underway. The rarity of cases complicates large-scale human studies, and standard regulatory timelines—absent emergency funding or accelerated pathways—make licensure this year improbable despite heightened attention from the 2026 MV Hondius outbreak. New data releases or trial initiations could shift sentiment, but current evidence supports the market-implied odds.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
市场开放时间： May 4, 2026, 10:39 AM ET
交易量
$136,356结束日期
2027-01-01市场开放时间
May 4, 2026, 10:39 AM ETThis market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus heavily favors no hantavirus vaccine approval in 2026, reflecting the early-stage status of all candidates.** Authoritative sources including the WHO and CDC confirm no licensed vaccine exists for New World hantaviruses such as Andes virus, with only limited inactivated products used regionally in Asia for other strains. Promising mRNA and DNA candidates from groups like UTMB, USAMRIID, and Moderna-Korea University collaborations remain in preclinical or Phase 1 testing, with no Phase 3 efficacy trials underway. The rarity of cases complicates large-scale human studies, and standard regulatory timelines—absent emergency funding or accelerated pathways—make licensure this year improbable despite heightened attention from the 2026 MV Hondius outbreak. New data releases or trial initiations could shift sentiment, but current evidence supports the market-implied odds.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
交易量
$136,356结束日期
2027-01-01市场开放时间
May 4, 2026, 10:39 AM ET**Trader consensus heavily favors no hantavirus vaccine approval in 2026, reflecting the early-stage status of all candidates.** Authoritative sources including the WHO and CDC confirm no licensed vaccine exists for New World hantaviruses such as Andes virus, with only limited inactivated products used regionally in Asia for other strains. Promising mRNA and DNA candidates from groups like UTMB, USAMRIID, and Moderna-Korea University collaborations remain in preclinical or Phase 1 testing, with no Phase 3 efficacy trials underway. The rarity of cases complicates large-scale human studies, and standard regulatory timelines—absent emergency funding or accelerated pathways—make licensure this year improbable despite heightened attention from the 2026 MV Hondius outbreak. New data releases or trial initiations could shift sentiment, but current evidence supports the market-implied odds.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题